Trade Beam Therapeutics Inc. - BEAM CFD

Add to favourite

23.79

2.23%

0.13

Low: 23.68

High: 24.79

Market Trading Hours* (UTC) Open now
Closes on Friday at 20:00

Mon - Fri: 13:30 - 20:00

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.13

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Beam Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	24.26
Open*	24.44
1-Year Change*	-21.24%
Day's Range*	23.68 - 24.79
52 wk Range	16.95-50.74
Average Volume (10 days)	974.71K
Average Volume (3 months)	29.78M
Market Cap	1.91B
P/E Ratio	-100.00K
Shares Outstanding	81.50M
Revenue	81.55M
EPS	-4.18
Dividend (Yield %)	N/A
Beta	1.67
Next Earnings Date	Feb 26, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	24.26	0.26	1.08%	24.00	24.67	23.97
Apr 17, 2024	24.23	-1.69	-6.52%	25.92	26.01	24.08
Apr 16, 2024	25.64	0.64	2.56%	25.00	25.83	24.79
Apr 15, 2024	25.59	-0.39	-1.50%	25.98	26.25	25.07
Apr 12, 2024	25.85	-0.87	-3.26%	26.72	26.86	25.47
Apr 11, 2024	27.19	-0.06	-0.22%	27.25	27.46	26.62
Apr 10, 2024	26.98	-0.34	-1.24%	27.32	27.59	26.62
Apr 9, 2024	29.25	0.78	2.74%	28.47	29.27	28.09
Apr 8, 2024	28.72	0.50	1.77%	28.22	28.79	27.95
Apr 5, 2024	28.11	-0.12	-0.43%	28.23	28.67	27.98
Apr 4, 2024	28.95	-0.73	-2.46%	29.68	30.01	28.83
Apr 3, 2024	29.61	-0.37	-1.23%	29.98	30.65	29.53
Apr 2, 2024	30.47	0.22	0.73%	30.25	30.86	29.95
Apr 1, 2024	32.60	-0.15	-0.46%	32.75	32.86	31.55
Mar 28, 2024	32.96	-1.09	-3.20%	34.05	34.11	32.86
Mar 27, 2024	33.90	0.45	1.35%	33.45	34.13	32.73
Mar 26, 2024	33.14	-0.81	-2.39%	33.95	34.44	33.13
Mar 25, 2024	33.62	0.10	0.30%	33.52	34.17	33.29
Mar 22, 2024	33.55	-1.12	-3.23%	34.67	34.69	33.33
Mar 21, 2024	34.88	-0.61	-1.72%	35.49	36.56	34.49

Beam Therapeutics Inc. Events

Time (UTC)	Country	Event
Wednesday, May 8, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 Beam Therapeutics Inc Earnings Release Q1 2024 Beam Therapeutics Inc Earnings Release Forecast - Previous -
Wednesday, June 5, 2024
Time (UTC) 15:30	Country US	Event Beam Therapeutics Inc Annual Shareholders Meeting Beam Therapeutics Inc Annual Shareholders Meeting Forecast - Previous -
Tuesday, August 6, 2024
Time (UTC) 12:30	Country US	Event Q2 2024 Beam Therapeutics Inc Earnings Release Q2 2024 Beam Therapeutics Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	60.92	51.844	0.024	0.018	0
Total Operating Expense	399.399	444.309	132.784	75.172	45.741
Selling/General/Admin. Expenses, Total	87.805	57.222	29.605	20.553	11.868
Research & Development	311.594	387.087	103.179	54.619	33.873
Operating Income	-338.479	-392.465	-132.76	-75.154	-45.741
Interest Income (Expense), Net Non-Operating	59.397	-1.009	-61.832	-3.101	-11.457
Other, Net	18.904	22.836		-0.071	-59.54
Net Income Before Taxes	-260.178	-370.638	-194.592	-78.326	-116.738
Net Income After Taxes	-263.588	-370.638	-194.592	-78.326	-116.738
Minority Interest				0	1.481
Net Income Before Extra. Items	-289.088	-370.638	-194.592	-78.326	-115.257
Net Income	-289.088	-370.638	-194.592	-78.326	-115.257
Total Adjustments to Net Income	0	0	-1.277	-12.714	-2.068
Income Available to Common Excl. Extra. Items	-289.088	-370.638	-195.869	-91.04	-117.325
Income Available to Common Incl. Extra. Items	-289.088	-370.638	-195.869	-91.04	-117.325
Diluted Net Income	-289.088	-370.638	-195.869	-91.04	-117.325
Diluted Weighted Average Shares	70.0153	64.2277	46.7332	45.3248	45.3248
Diluted EPS Excluding Extraordinary Items	-4.12893	-5.77069	-4.19122	-2.00861	-2.58854
Dividends per Share - Common Stock Primary Issue					0
Diluted Normalized EPS	-4.12893	-5.77069	-4.19122	-2.00861	-2.58854
Revenue	60.92	51.844	0.024	0.018
Equity In Affiliates	-25.5

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	20.116	24.208	20.037	15.799	16.652
Revenue	20.116	24.208	20.037	15.799	16.652
Total Operating Expense	122.264	123.136	109.022	107.102	98.618
Selling/General/Admin. Expenses, Total	24.656	23.49	22.681	21.815	24.062
Research & Development	97.608	99.646	86.341	85.287	74.556
Operating Income	-102.148	-98.928	-88.985	-91.303	-81.966
Interest Income (Expense), Net Non-Operating	17.201	2.764	32.189	10.513	10.136
Other, Net	2.171	-0.296	19.447	-0.875	-0.12
Net Income Before Taxes	-82.776	-96.46	-37.349	-81.665	-71.95
Net Income After Taxes	-82.776	-96.46	-38.349	-84.075	-71.95
Net Income Before Extra. Items	-82.776	-96.46	-38.349	-109.575	-71.95
Net Income	-82.776	-96.46	-38.349	-109.575	-71.95
Income Available to Common Excl. Extra. Items	-82.776	-96.46	-38.349	-109.575	-71.95
Income Available to Common Incl. Extra. Items	-82.776	-96.46	-38.349	-109.575	-71.95
Diluted Net Income	-82.776	-96.46	-38.349	-109.575	-71.95
Diluted Weighted Average Shares	76.3352	72.2738	70.7859	70.3432	70.2102
Diluted EPS Excluding Extraordinary Items	-1.08438	-1.33465	-0.54176	-1.55772	-1.02478
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-1.08438	-1.33465	-0.54176	-1.55772	-1.02478
Total Adjustments to Net Income			0
Equity In Affiliates			0	-25.5

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	1092.9	1273.01	308.321	94.544	148.275
Cash and Short Term Investments	1078.13	965.647	299.671	91.848	146.443
Cash & Equivalents	232.767	559.994	162.171	37.221	146.443
Prepaid Expenses	14.762	7.36	8.65	2.696	1.832
Total Assets	1341.71	1474.45	451.677	156.099	167.012
Property/Plant/Equipment, Total - Net	234.133	186.976	125.372	43.247	16.944
Property/Plant/Equipment, Total - Gross	264.303	203.057	134.271	47.411	17.605
Accumulated Depreciation, Total	-30.17	-16.081	-8.899	-4.164	-0.661
Other Long Term Assets, Total	14.685	14.47	17.984	18.308	1.793
Total Current Liabilities	223.595	213.435	102.337	29.138	25.587
Accounts Payable	9.029	7.474	6.314	7.846	7.351
Accrued Expenses	58.439	75.204	22.705	12.189	1.734
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	1.853	2.287	2.118	1.303	13.75
Other Current Liabilities, Total	154.274	128.47	71.2	7.8	2.752
Total Liabilities	608.24	647.715	206.116	55.154	32.984
Total Long Term Debt	1.154	3.007	5.294	4.411	0
Other Liabilities, Total	383.491	431.273	98.485	21.605	7.397
Total Equity	733.474	826.738	245.561	100.945	134.028
Redeemable Preferred Stock	0	0	0	302.049	251.434
Common Stock	0.712	0.684	0.573	0.073	0.25
Additional Paid-In Capital	1792.55	1594.38	642.633	1.851	7.062
Retained Earnings (Accumulated Deficit)	-1057.36	-768.274	-397.636	-203.044	-124.718
Total Liabilities & Shareholders’ Equity	1341.71	1474.45	451.677	156.099	167.012
Total Common Shares Outstanding	71.2773	68.3894	57.2542	45.3248	45.3248
Short Term Investments	845.367	405.653	137.5	54.627
Capital Lease Obligations	1.154	3.007	5.294	4.411
Other Equity, Total	-2.43	-0.05	-0.009	0.016
Total Receivables, Net	0	300
Accounts Receivable - Trade, Net	0	300

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	1039.54	1094.81	1083.03	1092.9	1108.91
Cash and Short Term Investments	1015.46	1073.02	1059.47	1078.13	1094.55
Cash & Equivalents	169.049	225.544	249.771	232.767	156.511
Short Term Investments	846.408	847.472	809.7	845.367	938.043
Prepaid Expenses	24.084	21.789	23.56	14.762	14.358
Total Assets	1290.53	1353.89	1332.35	1341.71	1350.25
Property/Plant/Equipment, Total - Net	239.661	242.278	237.981	234.133	226.714
Property/Plant/Equipment, Total - Gross	284.481	281.911	272.798	264.303	252.94
Accumulated Depreciation, Total	-44.82	-39.633	-34.817	-30.17	-26.226
Other Long Term Assets, Total	11.332	16.804	11.34	14.685	14.624
Total Current Liabilities	220.365	209.536	219.925	223.595	238.859
Accounts Payable	3.177	6.886	14.063	9.029	7.024
Accrued Expenses	53.72	49.011	49.004	58.439	48.423
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	1.084	0.912	1.421	1.853	2.21
Other Current Liabilities, Total	162.384	152.727	155.437	154.274	181.202
Total Liabilities	511.593	542.244	570.846	608.24	635.773
Total Long Term Debt	0.304	0.875	0.983	1.154	1.388
Capital Lease Obligations	0.304	0.875	0.983	1.154	1.388
Other Liabilities, Total	290.924	331.833	349.938	383.491	395.526
Total Equity	778.941	811.643	761.506	733.474	714.477
Common Stock	0.794	0.78	0.744	0.712	0.705
Additional Paid-In Capital	2112.86	2049.48	1915.35	1792.55	1737.46
Retained Earnings (Accumulated Deficit)	-1332.69	-1236.6	-1153.82	-1057.36	-1019.01
Other Equity, Total	-2.024	-2.015	-0.765	-2.43	-4.674
Total Liabilities & Shareholders’ Equity	1290.53	1353.89	1332.35	1341.71	1350.25
Total Common Shares Outstanding	79.382	77.9535	74.4354	71.2773	70.4577
Total Receivables, Net				0	0
Accounts Receivable - Trade, Net				0	0
Long Term Investments
Redeemable Preferred Stock	0	0		0	0

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-289.088	-370.638	-194.592	-78.326	-116.738
Cash From Operating Activities	22.527	-66.268	-95.741	-72.003	-20.298
Cash From Operating Activities	14.147	7.451	4.735	3.503	0.65
Non-Cash Items	45.84	185.665	88.769	13.525	85.715
Changes in Working Capital	251.628	111.254	5.347	-10.705	10.075
Cash From Investing Activities	-461.336	-294.144	-100.123	-66.659	-13.424
Capital Expenditures	-48.951	-46.811	-16.357	-12.518	-13.124
Other Investing Cash Flow Items, Total	-412.385	-247.333	-83.766	-54.141	-0.3
Cash From Financing Activities	111.59	756.141	322.322	41.279	179.727
Issuance (Retirement) of Stock, Net	114.065	767.075	322.683	38.086	179.727
Net Change in Cash	-327.219	395.729	126.458	-97.383	146.005
Financing Cash Flow Items	-0.188	-8.816	-2.059	-2.521
Issuance (Retirement) of Debt, Net	-2.287	-2.118	1.698	5.714
Cash Interest Paid	0.376	0.567	0.561

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-96.46	-289.088	-250.739	-141.164	-69.214
Cash From Operating Activities	-109.815	22.527	91.718	166.214	218.49
Cash From Operating Activities	4.647	14.147	10.203	6.73	3.312
Non-Cash Items	26.832	45.84	70.275	28.296	13.278
Cash Interest Paid	0.062	0.376	0.3	0.214	0.113
Changes in Working Capital	-44.834	251.628	261.979	272.352	271.114
Cash From Investing Activities	25.451	-461.336	-574.775	-538.601	-537.339
Capital Expenditures	-6.017	-48.951	-40.69	-28.903	-7.259
Other Investing Cash Flow Items, Total	31.468	-412.385	-534.085	-509.698	-530.08
Cash From Financing Activities	98.416	111.59	79.578	78.016	55.676
Financing Cash Flow Items	-0.062	-0.188	-0.134	-0.109	-0.006
Issuance (Retirement) of Stock, Net	99.081	114.065	81.409	79.243	56.235
Issuance (Retirement) of Debt, Net	-0.603	-2.287	-1.697	-1.118	-0.553
Net Change in Cash	14.052	-327.219	-403.479	-294.371	-263.173

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Beam Therapeutics Inc. Company profile

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children''s Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Industry:

Biotechnology & Medical Research (NEC)

26 Landsdowne St
CAMBRIDGE
MASSACHUSETTS 02139-4216
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024